Palisade Bio, Inc. (PALI)
NASDAQ: PALI · IEX Real-Time Price · USD
4.201
-0.129 (-2.98%)
Jul 22, 2024, 11:08 AM EDT - Market open
Palisade Bio Employees
Palisade Bio had 9 employees as of December 31, 2023. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,500,333
Market Cap
4.03M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9 | -3 | -25.00% |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| China Pharma Holdings | 231 |
| OpGen | 100 |
| iSpecimen | 53 |
| Sintx Technologies | 43 |
| Genprex | 26 |
| Onconetix | 12 |
| CERo Therapeutics Holdings | 9 |
| MyMD Pharmaceuticals | 6 |
PALI News
- 3 days ago - Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108 - GlobeNewsWire
- 11 days ago - Palisade Bio Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product - GlobeNewsWire
- 4 weeks ago - Palisade Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 4 weeks ago - Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences - GlobeNewsWire
- 5 weeks ago - Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108 - GlobeNewsWire
- 6 weeks ago - Palisade Bio to Present at the Virtual Investor Pitch Conference - GlobeNewsWire
- 2 months ago - Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models - GlobeNewsWire
- 2 months ago - Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire